BNTX

BioNTech SEC

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$130.00

Analysis reference price unavailable

Analysis 2026-08-05 · RankAlpha Sentiment Codex

Most likely

Base case

50%

Probability

Target price

$95.00

Analysis reference price unavailable

Analysis 2026-08-05 · RankAlpha Sentiment Codex

B-

Bear case

25%

Probability

Target price

$70.00

Analysis reference price unavailable

Analysis 2026-08-05 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-08-05

AI commentary

News tone is mixed: vaccine authorization and pipeline progress are supportive, while coverage reported post-earnings share weakness and revenue pressure. Social data, a verified Q2 company release or transcript, and post-print analyst revisions were unavailable; sentiment is therefore a cautious monitoring signal rather than positive confirmation.

RankAlpha Sentiment Codex - 2026-08-05

Open full AI memo

Evidence flagged

peer set is too generic or lacks enough direct operating comparators; memo remains a monitoring view with limited forward evidence and should not be standard-conviction

Impact

tentative

Confidence

AI events

2026-08-05catalystPost-print skepticism and COVID revenue erosionMedium impact

Recent coverage linked weakness in Pfizer and BioNTech shares to earnings. BioNTech's verified Q1 filing reported €118.1 million of revenue, a €531.9 million net loss, 2026 revenue guidance of €2.0–2.3 billion, and anticipated lower COVID-19 vaccine revenues; without a verified Q2 release in the retrieved evidence, this remains a sentiment risk rather than a confirmed earnings miss. [#SEC-6K-2026-05-05]

2026-12-31event2026 late-stage oncology readout clusterHigh impact

BioNTech identified six late-stage pipeline data readouts expected in 2026, spanning pumitamig, gotistobart, antibody-drug conjugates, and mRNA cancer immunotherapies. Positive data could support a rerating, but timing and outcomes remain uncertain. [#SEC-6K-2026-05-05]

2026-12-31catalystPumitamig pivotal-program execution with Bristol Myers SquibbHigh impact

BioNTech reported that five additional pivotal pumitamig trials were initiated in 2026 with Bristol Myers Squibb, while company-reported ROSETTA Lung-02 data highlighted encouraging efficacy. Sustained execution and confirmatory data are the key long-duration value driver. [#SEC-6K-2026-05-05][#IR-2026-05-30]

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-08-05 • Updated nightlySource: Internal modelMethodology